Peng D, Hu T, Soutto M, Belkhiri A, Zaika A, El-Rifai W
Touti, F., Lautrette, G., Johnson, K.D., Delaney, J.C., Wollacott, A., Tissire, H., et al., ChemBioChem , 2018, vol
10 Semaglutide has demonstrated significant cardiovascular benefits, particularly in reducing the risk of major adverse cardiovascular events, such as heart attacks and strokes
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for managing type 2 diabetes mellitus, though some are now also licensed for weight management in individuals with obesity
Standard practice uses 25-gauge 1-inch needles, but 27-gauge 1.25-inch needles reduce injection pain significantly while ensuring intramuscular (not subcutaneous) delivery in patients with body fat percentages above 25%